Stockscreener 앱 받기
1.03
3.00%
0.03
시간 외 거래:
1.01
-0.02
-1.94%
전일 마감가:
$1.00
열려 있는:
$1
하루 거래량:
1.07M
Relative Volume:
0.50
시가총액:
$118.81M
수익:
$13.45M
순이익/손실:
$-178.23M
주가수익비율:
-0.6242
EPS:
-1.65
순현금흐름:
$-132.53M
1주 성능:
+6.85%
1개월 성능:
-32.68%
6개월 성능:
-11.97%
1년 성능:
-50.24%
1일 변동 폭
$0.9651
$1.045
1주일 범위
$0.96
$1.105
52주 변동 폭
$0.6611
$3.43
Fate Therapeutics Inc Stock (FATE) Company Profile
명칭
Fate Therapeutics Inc
전화
858.875.1803
주소
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
FATE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.03 | 115.35M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-11-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-06-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-01-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-12-15 | 개시 | Goldman | Sell |
| 2022-11-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-08-18 | 재개 | Wells Fargo | Overweight |
| 2022-07-28 | 개시 | Needham | Hold |
| 2022-07-11 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-11 | 재개 | BMO Capital Markets | Market Perform |
| 2021-12-15 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-11-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-26 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-07 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Jefferies | Buy |
| 2021-02-26 | 개시 | BofA Securities | Buy |
| 2021-02-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-02-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-27 | 재개 | H.C. Wainwright | Neutral |
| 2020-05-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-09 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | 재확인 | Mizuho | Buy |
| 2019-12-09 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-06 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-07-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-06-07 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2019-03-28 | 개시 | SVB Leerink | Outperform |
| 2019-01-03 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | 개시 | Jefferies | Buy |
| 2018-08-01 | 개시 | Citigroup | Buy |
| 2018-03-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
모두보기
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
Cantor Fitzgerald Issues Positive Outlook for FATE Earnings - MarketBeat
Multi factor analysis applied to Fate Therapeutics Inc.July 2025 Action & Free Growth Oriented Trading Recommendations - newser.com
Tools to monitor Fate Therapeutics Inc. recovery probabilityBuy Signal & Growth Oriented Trade Recommendations - newser.com
Automated trading signals detected on Fate Therapeutics Inc.Short Setup & Accurate Buy Signal Alerts - newser.com
Will Fate Therapeutics Inc. stock outperform Nasdaq indexQuarterly Portfolio Report & Precise Entry and Exit Recommendations - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Is Fate Therapeutics Inc. stock undervalued vs historical averagesEarnings Trend Report & Capital Efficient Trade Techniques - newser.com
Exit strategy if you’re trapped in Fate Therapeutics Inc.Portfolio Return Summary & Daily Entry Point Trade Alerts - newser.com
Will Fate Therapeutics Inc. see short term momentumEarnings Risk Summary & Real-Time Volume Spike Alerts - newser.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Brokerages - MarketBeat
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts - TipRanks
How sentiment analysis helps forecast Fate Therapeutics Inc.2025 Pullback Review & Free Growth Oriented Trading Recommendations - newser.com
Published on: 2025-11-16 18:05:52 - newser.com
Will Fate Therapeutics Inc. stock recover faster than market2025 EndofYear Setup & Safe Entry Zone Tips - newser.com
Fate Therapeutics (FATE) Receives a Hold from Bank of America Securities - The Globe and Mail
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks - TipRanks
Why Fate Therapeutics Inc. stock remains a top recommendationPortfolio Gains Report & Verified Stock Trade Ideas - newser.com
How resilient is Fate Therapeutics Inc. stock in market downturns2025 AllTime Highs & Weekly High Return Opportunities - newser.com
Fate Therapeutics (NASDAQ:FATE) Announces Quarterly Earnings Results - MarketBeat
Fate Therapeutics: Q3 Earnings Snapshot - Connecticut Post
Analyzing drawdowns of Fate Therapeutics Inc. with statistical tools2025 Fundamental Recap & Free Fast Entry Momentum Trade Alerts - newser.com
Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating - 富途牛牛
Fate Therapeutics earnings beat by $0.03, revenue topped estimates - Investing.com Canada
Fate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
Fate Therapeutics Q3 net loss widens - MarketScreener
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates - The Manila Times
FATE THERAPEUTICS INC SEC 10-Q Report - TradingView
Why Fate Therapeutics Inc. stock is a value investor pickJuly 2025 EndofMonth & Precise Entry and Exit Recommendations - newser.com
Fate Therapeutics Inc (FATE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Fate Therapeutics Inc 주식 (FATE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Valamehr Bahram | President and CEO |
Aug 04 '25 |
Sale |
1.06 |
14,466 |
15,396 |
334,898 |
1.38%
1.42%
자본화:
|
볼륨(24시간):